[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356858-105":59,"doc-detail-356858-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","triptolide-enhances-anti-cancer-activities-of-irinotecan-in-human-colon-cancer-ht-29-cells-in-vitro-and-ht-29-cell-xenograft-tumor-model-in-nude-mice","Triptolide enhances anti-cancer activities of irinotecan in human colon cancer HT-29 cells in vitro and HT-29 cell xenograft tumor model in nude mice","","Irinotecan is an anticancer drug for solid tumors, including colorectal cancer, but its clinical use is constrained by significant side effects. Triptolide, an alkaloid from Tripterygium wilfordii, has been used against malignancies in China, yet its combined effects with irinotecan in colon cancer remain insufficiently characterized. In vitro experiments assessed HT-29 cells treated with irinotecan, triptolide, or both, with combination treatment reducing viable cells and promoting apoptosis markers. In vivo, HT-29 xenografts in nude mice received combination therapy for 30 days, with tumor volume reduction and organ function safety signals supported by H&E and immunohistochemistry results.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/triptolide-enhances-anti-cancer-activities-of-irinotecan-in-human-colon-cancer-ht-29-cells-in-vitro-and-ht-29-cell-xenograft-tumor-model-in-nude-mice/356858/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/triptolide-enhances-anti-cancer-activities-of-irinotecan-in-human-colon-cancer-ht-29-cells-in-vitro-and-ht-29-cell-xenograft-tumor-model-in-nude-mice/356858.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding irinotecan in colorectal cancer?","Question",{"text":112,"@type":113},"Irinotecan is effective against solid tumors including colorectal cancer, but its clinical application is limited by adverse side effects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the in vitro experiments conducted for HT-29 colon cancer cells?",{"text":117,"@type":113},"Human HT-29 cells were treated with irinotecan, triptolide, or both combinations, and cell viability and apoptosis-related protein changes were evaluated.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the in vivo xenograft results show about combining triptolide with irinotecan?",{"text":121,"@type":113},"In nude mice bearing HT-29 xenograft tumors, combination therapy reduced tumor growth over 30 days, supported by increased cleaved caspase expression and tissue staining showing no major organ toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356858,1790197243,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Triptolide enhances anti-cancer activities of irinotecan in human colon cancer HT-29 cells in vitro and HT-29 cell xenograft tumor model in nude mice  \nYi-Shih Ma, MD, PhD 1,2, Fu-Shin Chueh, PhD3, Yi-Ping Huang, PhD4, Shu-Fen Peng, PhD4,5, Chao-Lin Kuo, PhD4, Jaw-Chyun Chen, PhD6,  \nIntegrative Cancer Therapies Volume 25: 1–14 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15347354261448871](DOI: 10.1177/15347354261448871)[ ](DOI: 10.1177/15347354261448871)[journals.sagepub.com/home/ict](journals.sagepub.com/home/ict)  \nFei-Ting Hsu, PhD7, Kuang-Chi Lai, MD, PhD4,8* , and Yu-Jung Lin, Mr9*  \nAbstract  \nIrinotecan (IRI), a clinically used anticancer drug, is effective against various solid tumors, including colorectal cancer, but its use is limited by side effects. Triptolide (TP), an alkaloid from Tripterygium wilfordii, has been used to treat malignancies in China, though its combined effects with IRI on colon cancer cells are not well-documented. In vitro, human colon cancer HT-29 cells were treated with IRI, TP, or both combinations. Results showed that the combination of IRI and TP significantly decreased viable cell numbers more than IRI or TP alone. IRI combined with TP also led to higher Bax and lower Bcl-2 levels, as well as increased cleaved caspase-8, -9, and-3. These findings suggest that TP enhances apoptosis in HT-29 cells and may potentiate the anticancer effects of IRI by disrupting the balance of pro-and anti-apoptotic proteins, which plays a crucial role in controlling tumor cell survival. In vivo, HT-29 cell-xenograft nude mice were treated with IRI, TP, or both combinations for 30 days. Tumor volume and body weight were measured every 2 days, and liver and kidney functions (ALT, AST, CREA, GGT) were assessed. H&E staining of tissues revealed no significant toxicity in the heart, lungs, liver, kidneys, spleen, or small intestine, suggesting that the combination therapy does not induce major organ damage. Immunohistochemical (IHC) analysis showed that IRI combined with TP resulted in higher expression ofcleaved-caspase-3, -8, and-9 compared to IRI or TP alone, indicating enhanced tumor cell apoptosis. These results suggest that TP enhances IRI’s anti-cancer effects by promoting apoptosis in colon cancer cells. TP may thus serve as a potential enhancer for IRI in future colon cancer treatments, offering a novel strategy to improve therapeutic outcomes, enhance drug efficacy, and minimize side effects.  \nKeywords  \nirinotecan, triptolide, HT-29 colon cancer cells, xenograft, caspase, apoptosis  \nReceived: February 8, 2025; accepted: April 20, 2026  \n1 I-Shou University, Kaohsiung, Taiwan 2E-Da Cancer Hospital, Kaohsiung, Taiwan 3Asia University, Taichung, Taiwan  \n4China Medical University, Taichung, Taiwan 5China Medical University Hospital, Taichung, Taiwan 6Da-Yeh University, Changhua, Taiwan  \n7National Central University, Taoyuan, Taiwan  \n8Chung Hwa University of Medical Technology, Tainan, Taiwan 9Chang Bing Show-Chwan Memorial Hospital, Changhua County, Taiwan *These authors contributed equally to this work  \nCorresponding Authors:  \nKuang-Chi Lai, Department of Surgery, College of Medicine, China Medical University, Taichung 404, Taiwan.  \nEmail: [kuangchilai@gmail.com](kuangchilai@gmail.com)  \nYu-Jung Lin, Department of Pharmacy, Chang Bing Show-Chwan Memorial Hospital, No.6, Lugong Rd., Lukang Township, Changhua County 505, Taiwan.  \nEmail: [7568@cbshow.org.tw](7568@cbshow.org.tw)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified o","cbCaihVJor31STYG","https://ap.wps.com/l/cbCaihVJor31STYG","pdf",4476949,14,"English","# Abstract\n# Introduction","[{\"question\":\"What problem does the study address regarding irinotecan in colorectal cancer?\",\"answer\":\"Irinotecan is effective against solid tumors including colorectal cancer, but its clinical application is limited by adverse side effects.\"},{\"question\":\"How were the in vitro experiments conducted for HT-29 colon cancer cells?\",\"answer\":\"Human HT-29 cells were treated with irinotecan, triptolide, or both combinations, and cell viability and apoptosis-related protein changes were evaluated.\"},{\"question\":\"What did the in vivo xenograft results show about combining triptolide with irinotecan?\",\"answer\":\"In nude mice bearing HT-29 xenograft tumors, combination therapy reduced tumor growth over 30 days, supported by increased cleaved caspase expression and tissue staining showing no major organ toxicity.\"}]","Triptolide enhances anti-cancer activities of irinotecan in human colon cancer HT-29 cells in vitro and HT-29 cell xenograft tumor model in nude mice | PDF",1790127727,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9e96caf5b24a7a6b3ca2ae8870b109d.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5090ce29cc65e87fbdf5b709a37432a.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2f7f1d817298948b968fe1f75c0f7f0.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da025ae552764f98b28446793c706d66.webp",980,1272]